Tool
Provider Match: Narrow the Field by What Actually Constrains You
Answers four questions and filters our captured records to the providers that fit. It runs entirely in your browser, stores nothing, and does not rank the results — becau
Answers four questions and filters our captured records to the providers that fit. It runs entirely in your browser, stores nothing, and does not rank the results — because six of 54 prices are verified and a ranking on that basis would sort by disclosure rather than quality.
Nothing is stored or transmitted. No health information is requested.
What this does and does not do
It filters. It does not rank, score or recommend, and it will not tell you which provider is best — because with six of 54 prices independently captured, any ranking would sort providers by how much they publish rather than by how good they are.
Every result carries its evidence status. Where a figure is provider-reported, the result says so.
The answer it gives everyone first
If you have not checked insurance, check insurance. A covered brand GLP-1 can land near $25 a month, and eligible Medicare enrollees pay $50 through the GLP-1 Bridge until the end of 2027. Both are below every self-pay route in our dataset, including every compounded programme.
The tool will say this before showing you anything else, because it is true more often than any other result it can produce.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Related on this site
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- Tirzepatide Provider ReviewsProviders
- Tirzepatide Provider Comparison ToolTools
- Tirzepatide Price Comparison by ProviderPillar / Money
- Tirzepatide Cost Without InsurancePillar / Money
- Shed Tirzepatide ReviewProviders
- Questions to Ask a GLP-1 ClinicianTools
- Privacy PolicyCore & Trust
GLP-1 Tirzepatide Review. “Provider Match: Narrow the Field by What Actually Constrains You.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/tools/provider-match/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.